Bausch Health (BHC)
(Delayed Data from NYSE)
$8.48 USD
-0.28 (-3.20%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $8.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.48 USD
-0.28 (-3.20%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $8.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum A VGM
Zacks News
Bausch Health (BHC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
UnitedHealth (UNH) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) Q4 results reflect higher revenues, driven by segmental contributions, partly offset by steep expenses.
Bausch (BHC) Eye Care Business Files for IPO in the US & Canada
by Zacks Equity Research
Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.
Why Is Bausch (BHC) Down 15.6% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Bausch Health (BHC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Increase Y/Y
by Zacks Equity Research
Anthem's (ANTM) third-quarter results reflect higher revenues and solid contribution from its segments.
What's in Store for HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to reflect better revenues owing to higher patient volumes.
Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal
by Zacks Equity Research
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AptarGroup (ATR) Buys Stake in Voluntis, Boosts Capabilities
by Zacks Equity Research
AptarGroup (ATR) completes the acquisition of 64.6% stake in Voluntis, which will help expand its digital healthcare offerings and drive innovation in the healthcare space.
Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.
Bausch Health (BHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Bausch (BHC) Might Surprise This Earnings Season
by Zacks Equity Research
Bausch (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Why Bausch (BHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.